YS108R fermented milk alleviates DSS-induced colitis through the synergistic action of its core strain (Bifidobacterium longum subsp. longum YS108R) and its secreted exopolysaccharide, EPS1. On one hand, it inhibits the PI3K/Akt/NF-κB inflammatory pathway to mitigate immune responses. On the other hand, EPS1 upregulates the expression of tight junction proteins to repair the intestinal barrier, while simultaneously enriching beneficial bacteria such as Akkermansia muciniphila to promote mucosal healing.
In terms of application, this product utilizes advanced VPro-5 microencapsulation technology, which significantly enhances the survival rate of probiotics under extreme temperatures and during long-distance transportation. This not only overcomes the traditional limitations of cold chain logistics but also ensures that a sufficient quantity of highly active probiotics reaches the intestines. It provides a reliable ingredient solution for developing premium, long-shelf-life, ambient-temperature gut health products.